Julian Harrison
Stock Analyst at BTIG
(3.09)
# 1,230
Out of 4,960 analysts
38
Total ratings
46.88%
Success rate
2.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $24 → $25 | $13.91 | +79.73% | 2 | Jun 27, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $9.88 | +304.86% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $11.23 | +274.00% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $15.56 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $20.22 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $2.68 | +235.82% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.80 | +344.44% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $0.33 | +2,295.21% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $19.23 | +217.30% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $7.00 | +114.29% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $25 | $26.84 | -6.86% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $57.48 | -11.27% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $77.28 | -44.36% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $17.38 | +130.15% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $38.27 | +12.36% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $3.19 | +25.39% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $2.13 | +6,942.25% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $55.89 | -35.59% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $312.23 | - | 2 | Feb 11, 2022 |
Theravance Biopharma
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $13.91
Upside: +79.73%
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $9.88
Upside: +304.86%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $11.23
Upside: +274.00%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $15.56
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $20.22
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $2.68
Upside: +235.82%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.80
Upside: +344.44%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.33
Upside: +2,295.21%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $19.23
Upside: +217.30%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.00
Upside: +114.29%
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $26.84
Upside: -6.86%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $57.48
Upside: -11.27%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $77.28
Upside: -44.36%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $17.38
Upside: +130.15%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $38.27
Upside: +12.36%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $3.19
Upside: +25.39%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $2.13
Upside: +6,942.25%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $55.89
Upside: -35.59%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $312.23
Upside: -